CDH23: A Potential Drug Target and Biomarker for Multiple Chronic Diseases

Target Name: CDH23

NCBI ID: G64072

CDH23

CDH23: A Potential Drug Target and Biomarker for Multiple Chronic Diseases

Abstract:

CDH23, a member of the integrin alpha-2 (IAAG) family, is a cytoplasmic protein that plays a crucial role in various cellular processes, including cell adhesion, migration, and invasion. CDH23 has been identified as a potential drug target and biomarker for several chronic diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This review summarizes the current understanding of CDH23 as a drug target and biomarker, discusses the potential clinical applications of targeting this protein, and outlines future directions for research in this field.

Introduction:

CDH23 is a cytoplasmic protein that belongs to the integrin alpha-2 (IAAG) family. It is a key player in various cellular processes, including cell adhesion, migration, and invasion. CDH23 is expressed in a variety of tissues and cells, including neural cells, cancer cells, and immune cells. Its functions have been implicated in the development and progression of several chronic diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, CDH23 has become an attractive target for drug development for these diseases.

CDH23 as a Drug Target:

CDH23 has been identified as a potential drug target due to its unique structure and its involvement in various cellular processes. One of the key features of CDH23 is its ability to interact with various signaling molecules, including TGF-β, PDGF, and NF-kappa-B. These interactions enable CDH23 to regulate cell proliferation, migration, and invasion. CDH23 has also been shown to play a role in the development of cancer, as it has been found to be overexpressed in various types of cancer.

In addition to its role in cancer, CDH23 has also been linked to the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Studies have shown that CDH23 is overexpressed in the brains of individuals with these conditions, and that targeting this protein may be a promising approach for the development of new treatments for these debilitating diseases.

CDH23 as a Biomarker:

CDH23 has also been identified as a potential biomarker for several chronic diseases. Its expression has been shown to be elevated in individuals with various types of cancer, including breast, lung, and ovarian cancer. Additionally, CDH23 has been found to be overexpressed in individuals with neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. These findings suggest that CDH23 may be a useful biomarker for the diagnosis and evaluation of these conditions.

CDH23 has also been shown to be overexpressed in individuals with autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis. The potential implications of CDH23's overexpression in these conditions are that targeting this protein may be a promising approach for the development of new treatments for these autoimmune disorders.

Current Status of Research:

CDH23 has been identified as a potential drug target and biomarker for several chronic diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Further research is needed to fully understand the functions of CDH23 and its potential as a drug target and biomarker.

One approach to studying CDH23 is to use small molecules and antibodies to modulate its expression and activity. This approach has been used to study the effects of various small molecules on CDH23's stability and function. Additionally, researchers have used antibodies to study the interactions of CDH23 with various signaling molecules, including TGF-β, PDGF, and NF-kappa-B.

Another approach to studying CDH23 is to use cell-based assays to study its functions in various cellular processes, including cell adhesion, migration, and invasion. This approach has

Protein Name: Cadherin Related 23

Functions: Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells. CDH23 is required for establishing and/or maintaining the proper organization of the stereocilia bundle of hair cells in the cochlea and the vestibule during late embryonic/early postnatal development. It is part of the functional network formed by USH1C, USH1G, CDH23 and MYO7A that mediates mechanotransduction in cochlear hair cells. Required for normal hearing

The "CDH23 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDH23 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets